Adverse events873

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 20 of 873

Type	Event	Organ system	Group	Affected	At risk	Events
other	Abdominal abscess	Infections and infestations	Dose Escalation Phase 1 PF-02341066 and PD-0325901	1	25	1
other	Abdominal abscess	Infections and infestations	Dose Escalation Phase 2 PF-0341066 and Binimetinib	0	20	0
other	Abdominal abscess	Infections and infestations	Dose Expansion Phase	0	36	0
other	Abdominal Distension	Gastrointestinal disorders	Dose Escalation Phase 1 PF-02341066 and PD-0325901	0	25	0
other	Abdominal Distension	Gastrointestinal disorders	Dose Escalation Phase 2 PF-0341066 and Binimetinib	0	20	0
other	Abdominal Distension	Gastrointestinal disorders	Dose Expansion Phase	1	36	1
other	Abdominal Pain	Gastrointestinal disorders	Dose Escalation Phase 1 PF-02341066 and PD-0325901	3	25	3
other	Abdominal Pain	Gastrointestinal disorders	Dose Escalation Phase 2 PF-0341066 and Binimetinib	1	20	3
other	Abdominal Pain	Gastrointestinal disorders	Dose Expansion Phase	5	36	7
other	Abdominal Pain Lower	Gastrointestinal disorders	Dose Escalation Phase 1 PF-02341066 and PD-0325901	0	25	0
other	Abdominal Pain Lower	Gastrointestinal disorders	Dose Escalation Phase 2 PF-0341066 and Binimetinib	0	20	0
other	Abdominal Pain Lower	Gastrointestinal disorders	Dose Expansion Phase	1	36	1
other	Alanine Aminotransferase Increased	Investigations	Dose Escalation Phase 1 PF-02341066 and PD-0325901	3	25	5
other	Alanine Aminotransferase Increased	Investigations	Dose Escalation Phase 2 PF-0341066 and Binimetinib	3	20	4
other	Alanine Aminotransferase Increased	Investigations	Dose Expansion Phase	8	36	17
other	Alopecia	Skin and subcutaneous tissue disorders	Dose Escalation Phase 1 PF-02341066 and PD-0325901	1	25	1
other	Alopecia	Skin and subcutaneous tissue disorders	Dose Escalation Phase 2 PF-0341066 and Binimetinib	2	20	2
other	Alopecia	Skin and subcutaneous tissue disorders	Dose Expansion Phase	0	36	0
other	Amnesia	Nervous system disorders	Dose Escalation Phase 1 PF-02341066 and PD-0325901	0	25	0
other	Amnesia	Nervous system disorders	Dose Escalation Phase 2 PF-0341066 and Binimetinib	1	20	1

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02510001/events

API reference For AI assistants

Adverse events873

Sources 3

Read this list from software.